News | June 09, 2026
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
